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Abstract
Background: Interstitial duplications distal to 15q13 are very rare.
Case Presentation: Here, we reported a 14-year-old boy with severe short stature, delayed bone age,
hypogonadism, global developmental delay and intellectual disability. His had distinctive facial features including
macrocephaly, broad forehead, deep-set and widely spaced eyes, broad nose bridge, shallow philtrum and thick
lips. A de novo 6.4 Mb interstitial duplication of 15q15.3q21.2 was detected by chromosomal microarray analysis. We
compared our patient’s clinical phenotypes with those of several individuals with overlapping duplications and
several candidate genes responsible for the phenotypes were identified as well.
Conclusion: The results suggest a novel contiguous gene duplication syndrome characterized with shared features
including short stature, hypogonadism, global developmental delay and other congenital anomalies.
Keywords: Short stature , Hypogonadism, Global developmental delay, Intellectual disability, Interstitial
duplication15q15.3q21.2
Background
Microdeletions and microduplications are recurrent for
the proximal region of 15q. Five common breakpoints
(BP1–BP5) exist in the 15q11.2-q13 region. Deletions
between BP1–BP3 are responsible for the Prader-Willi
and Angelman syndromes, depending on the parent-of-
origin, whereas the reciprocal duplications of the region,
particular the gains of maternal copy of 15q11.2-q13, are
known as 15q duplication syndrome (Dup15q) charac-
terized by global developmental delay, autism spectrum
disorder and epilepsy [1–3]. 15q13.3 microdeletions and
microduplications between BP4–BP5 are enriched in
neurodevelopmental and neuropsychiatric disorders [4, 5].
On the other end of the 15q, the terminal trisomy or
tetrasomy of 15q, including IGF1R gene, is named as
15q26 overgrowth syndrome consisting of overgrowth,
learning difficulties, distinctive facial features and multiple
congenital anomalies [6]. The monosomy of 15q26 shows
the opposite growth features, such as pre- and postnatal
growth retardation, as well as some different dysmorphic
features [7]. A few proximal microdeletions at 15q25.2 have
been reported to be associated with congenital diaphrag-
matic hernia, cognitive deficits and Diamond-Blackfan
anemia and some more distal deletions to neurodevelop-
mental and neuropsychiatric disorders [8–11]. Whereas
duplications distal to 15q13 are very rare. Elcioglu (1997)
described a patient with hypogonadism, skeletal anomalies,
Marfan-like features, developmental delay and intellectual
disability, who carried a de novo interstitial inverted dupli-
cation involving bands of 15q13.3-q21.3 [12]. Herr (1983)
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reported a patient with a de novo interstitial duplication
of 15q14-q21.1, who presented with hypogonadism,
skeletal problems, short stature, delayed bone age, glo-
bal developmental delay and intellectual disability [13].
Both of the duplications were uncovered by high-resolution
G-banded cytogenetics analysis, so the precise locations
and sizes of the duplications were not determined [12, 13].
Here, we reported a de novo 6.4 Mb interstitial duplication
of 15q15.3q21.1 in a 14-year-old boy with hypogonadism,
short stature, global developmental delay and multiple con-
genital anomalies.
Case presentation
The proband is the fourth child of healthy unrelated
parents with negative family history. His siblings are all
healthy. Intrauterine growth retardation was noticed by
ultrasound examination at 7 months of pregnancy. He
was born by vaginal delivery at 38 weeks of gestation.
Birth weight was 2.9 kg (<-1SD), length 47 cm (<-2SD)
and head circumference 34 cm. Apgar scores were all 9.
No feeding difficulty was noted at all times.
The development milestones were delayed: he raised his
head at 4 months of age, sat at 9 months and independ-
ently walked at 1 year 6 months. Language development
was significantly delayed. The patient was examined at the
age of 14 years. His height was 140 cm (<-2SD), weight
33.5 kg (<-2SD) and head circumference 54 cm, which
indicated persistent failure to thrive. He had moderate
intellectual disability and showed poor performance in the
elementary school. His distinctive facial features were
characterized by macrocephaly, coarse face, broad fore-
head, deep-set and widely spaced eyes, strabismus, broad
nose bridge, shallow and short philtrum and thick lips. He
had severe short stature and hands X-ray showed delayed
bone age (Fig. 1). Yet his growth hormone level (6.19 ng/
ml) and level after provocation tests (11.6 ng/ml) were all
normal. Pituitary magnetic resonance imaging and thyroid
hormone level were also normal. Micropenis, small testes




Chromosomal microarray analysis was performed for the
proband and both parents by Affymetrix Cytoscan HD
Array (Affymetrix, USA). Genomic DNA was extracted
from peripheral blood using a commercial kit (Qiagen).
The labeling and hybridization procedures were performed
following manufacturer’s instructions. The raw data of
chromosomal microarray was analyzed by Affymetrix
Chromosome Analysis Suite Software.
Confirmation of 15q15.3q21.2 duplication
The duplication was further confirmed using quantita-
tive real-time PCR analysis. Primer sequences and de-
scriptions were included in Additional file 1: Table S1.
Results
A 6.4Mb duplication at 15q15.3q21.2 (chr15: 44,143,547–
50,572,601) was detected by CMA (Fig. 2). Parental tests
were normal. Thus, the proband carried a de novo copy
number variant. The duplication was further confirmed by
quantitative real-time PCR analysis (data not shown).
Discussion
Interstitial microdeletions and duplications involving 15q
except for the 15q11-q13 region were very rare. Here, we
reported a 14-year-old boy with severe short stature,
Fig. 1 The probandat 14 years of age. Note relative macrocephaly, coarse face, broad forehead, deep-set and widely spaced eyes, strabismus,
broad nose bridge, shallow philtrum, thick lips. Hand X-ray showed delayed bone age.
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delayed bone age, hypogonadism, global developmental
delay, intellectual disability and distinctive facial features,
who carried a de novo 6.4 Mb duplicationon 15q15.3q21.2.
No other clinical significant CNVs were detected in this pa-
tient. No duplication at this interval was reported in DGV.
It was reasonable to suggest that this de novo duplication
was likely pathogenic and mostly responsible for the pa-
tient’s clinical condition. Next we searched databases for
duplications overlapping with this region. We identified 3
cases from DECIPHER, 1 case from ISCA, 2 cases from lit-
eratures. The locations and sizes of these duplications are
depicted in Fig. 3 and their clinical information detailed in
Table 1.
Elcioglu (1997) [12] and Herr (1983) [13] each reported a
case with a de novo interstitial duplication on 15q13.3q21.3
and 15q14q21.1 respectively. The Decipher case 260222
Fig. 2 Affymetrix cytoscan HD array analysis including weighted log2 ratio (upper), copy number state (middle) and allele peaks (lower) are shown for
chromosome 15. The result shows duplication at 15q15.3q21.2. The genomic coordinates (hg19): chr15:44,143,547–50,572,601. The copy number gain
region is denoted by a blue bar
Fig. 3 Top panel shows a genome view of all duplication cases (blue colored custom tracks) relative to the genomic coordinates at 15q13.3q22 region,
extracted from Human Genome Build 37 (hg19). Red block diagram represents critical region of 15q21.1. Bottom panel shows the zoomed-in 15q21.1
region encompassing candidate genes. Note: Two patients reported by Herr and Elcioglu were detected by high resolution G-banding analysis, therefore
the genomic coordinates of the relevant bars were approximate locations.
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largely overlapped with the duplication detected in our pa-
tient. Our patient had the smallest duplication among these
four patients with large duplication centered on 15q21.1.
We noticed that three patients (our patient, Decipher case
260222 and the patient reported by Herr) had strikingly
similar clinical features including hypogonadism, short
stature, delayed bone age, global developmental delay and
intellectual disability. Interestingly, the patient reported by
Elcioglu shared most of similar phenotypes, but presented
with Marfan-like features such as tall stature. All duplica-
tions were de novo except for Decipher case 260222
without parental tests and not reported in DGV database,
as well as these patients had similar clinical conditions
especially hypogonadism and skeletal problems, which
further suggested a likely pathogenic nature of these
duplications.
To further support this notion, we identified several
candidate genes responsible for complex clinical pheno-
types. The FBN1 (134797) gene is involved in these
duplications. As we know that different mutations of
FBN1 gene cause different dominant genetic diseases
characterized with opposite stature. For example, acromic-
ric dysplasia caused by FBN1 mutations is characterized
by severe short stature, short limbs, delayed bone age, stiff
joints and facial dysmorphism [14]. Weill-Marchesani
syndrome caused by FBN1 mutations consists of short
stature, eye abnormalities, unusually brachydactyly, joint
stiffness and heart disease [15]. Marfan syndrome caused
by FBN1 mutations on the other hand is charaterized by
tall and slender stature with arachnodactyly, as well as
ocular and cardiovascular defects [16]. Thus, skeletal
anomalies could be explained by FBN1 gene duplication at
this interval.
Other than the FBN1 gene that was known to cause
skeletal problems, no other known disease gene at this
interval could explain all clinical phenotypes of these
patients. Smaller overlapping duplications shared by De-
cipher cases 250560 and 303564 and an ISCA case
1602971 involved the NOX family genes such as DUOX2,
DUOXA2, DUOXA1 and DUOX1. The loss of function
mutations in these genes could cause permanent conge-
nital hypothyroidism [17–20]. However, thyroid
Table 1 Genomic and clinical information of patients with duplication of 15q13.3q22. The genomic coordinates are based on
GRCH37/hg19
Reference Our patient Decipher
260222






















Size 6.4Mb 19.3Mb about 15Mb about 25Mb 330Kb 711Kb 780Kb










Phenotype hypogonadism, hypogonadism, hypogonadism, hypogonadism, ID, language delay, DD, MCA Cognitive
short stature, short stature, short stature, skeletal
problems,
macrocephaly, impairment





language delay delayed cranial
suture closure,
language delay, language delay,
















NA NA NA NA
Abbreviation: ID intellectual disability; DD developmental delay; MCA Multiple congenital anomalies; NA not available
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examinations of our patient and the one reported by Herr
were both normal and other patients were lack of this in-
formation, it may be inferred that the clinical consequence
of genes duplication was not known. And there was no
additional evidence to support the pathogenicity of these
small duplications.
Among other genes at the interval, we identified the
EID1 gene as an interesting candidate gene. EID1 was
shown to be expressed ubiquitously in human tissues with
high expression in neuron, cardiac and skeletal muscle
[21, 22]. Liu et al. generated an EID1 transgenic mouse
model that exhibited neuron-specific overexpression of
human EID1 gene in the brain, and overexpression of
EID1 reduced hippocampal long-term potentiation and
impaired spatial learning and memory function [23]. EID1
tightly interacted with CBP/p300 in the nuclei and had
been identified as an inhibitory protein of CBP/P300 [23].
CBP/p300, a family of CREB-binding proteins, was associ-
ated with Rubinstein–Taybi syndrome characterized by
short stature, intellectual disability, developmental delay
and distinctive facial features [24]. Overexpression of
EID1 in human brain could negatively regulate CBP/p300
activity and lead to the impairment of neuronal function.
In addition, EID-1 was known to be co-expressed with the
Steroidogenic factor-1 (SF-1) which played a critical role
in adrenal and reproductive development and function
[25, 26]. Park et al. provided convincing evidence demon-
strating that EID-1 strongly inhibited the transcriptional
activity of SF-1 [27]. It was tempting to speculate that
duplication of EID-1 may also be responsible for the hypo-
gonadism phenotype.
Finally, we identified the SEMA6D gene as another
candidate gene. SEMA6D gene, one member of the class
VI subgroup of the semaphorin family, was expressed
abundantly in kidney, brain, and placenta and moder-
ately in the heart and skeletal muscles. The expression
of SEMA6D predominantly in the adult tissues made
them potentially important molecules in nervous system
maintenance and repair. This profile was consistent with
a more general role of the proteins in neurogenesis and
organogenesis as well as in regenerative and degenera-
tive processes [28]. Therefore, we hypothesized that
overexpression of SEMA6D may play a role in neurode-
velopmental anomalies of our patient.
In conclusion, we reported a de novo duplication of
15q15.3q21.2 in a patient with skeletal problems, hypo-
gonadism, global developmental delay, intellectual dis-
ability and facial dysmorphism. Several candidate genes
responsible for the complex clinical features were identi-
fied and critical region centered on 15q21.1 was defined
as well, thus we proposed a novel contiguous gene
duplication syndrome at this genomic interval. Fur-
ther studies on duplications involving this region will
be necessary.
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